AstraZeneca, as part of its ongoing $3.5 billion investment in American innovation, opened its first U.S.-operated cell therapy factory in Maryland to help treat cancer patients. The U.K-based ...

HEADQUARTERS IN ROCKVILLE. THIS LAB ISN’T OPEN OR OPERATIONAL YET, BUT ONCE IT IS, THE FOLKS AT ASTRAZENECA BELIEVE IT IS GOING TO REVOLUTIONIZE CANCER TREATMENT. IT GIVES US HOPE. I MEAN.

AstraZeneca aims to widen the pool of bladder cancer patients who can be treated with its PD-L1 inhibitor Imfinzi after the drug demonstrated benefits in those with a higher-risk form of non ...

State officials and AstraZeneca marked the opening Monday of a cell therapy facility in Rockville that aims to create pathways to jobs for the state’s STEM professionals. AstraZeneca completed a ...

Controlling the entire cell therapy production process—from material receipt to product release—is “essential,” according to AstraZeneca, which says its new $300 million manufacturing ...

Astrazeneca could be opening a new facility in Rockville. California Gas Prices Could Skyrocket 75%, Newsom Is Warned Law and Order: SVU fans mourn loss of two main characters in surprise shakeup ...

May 8 (Reuters) - A federal appeals court on Thursday shut down AstraZeneca’s challenge to the U.S. government’s program that gives the Medicare health insurance plan the power to negotiate ...

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo (OTCPK:DSNKY) announced Wednesday that Enhertu, their jointly developed antibody-drug conjugate, reached the main goal in a Phase 3 trial in certain ...

The facility is part of AstraZeneca's $3.5 billion investment in U.S. research and manufacturing. Pope Leo XIV's voting history sparks speculation on political affiliation Rob Halford Explains Why ...

Drugmakers said it could cost them $1 trillion over the next decade. A U.S. appeals court shut down AstraZeneca’s challenge to the U.S. government program that gives Medicare the power to ...

On May 8, 2025, the Court of Appeals for the Third Circuit affirmed the district court’s dismissal of AstraZeneca’s challenges to the Inflation Reduction Act’s Drug Price Negotiation Program ...